Document Detail


Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?
MedLine Citation:
PMID:  16944377     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To compare late rectal toxicity rates after three-dimensional conformal radiotherapy to the prostate alone (P-3D-CRT) and whole-pelvis intensity-modulated radiotherapy along with a prostate boost (WP-IMRT/PB) to the same nominal total dose to the prostate. PATIENTS AND METHODS: 68 patients treated with conformal radiotherapy to the prostate only to 76 Gy at the National Institute for Cancer Research, Genoa, Italy, represented the first group (P-3D-CRT). The second group consisted of 45 patients treated at the University of Texas Medical Branch (UTMB), Galveston, TX, USA, with IMRT covering the pelvic nodes and seminal vesicles to 54 Gy at 1.8 Gy per fraction and the prostate to 60 Gy in the same 30 fractions. A separate phase boosted the prostate to 76 Gy (WP-IMRT/PB). Major aspects of planning were remarkably similar at both institutions leaving the inclusion or not of pelvic nodes as the main treatment-related difference between the two groups. Late rectal toxicity was prospectively scored according to the RTOG scale. All patients have a 12-month minimum follow-up, and mean follow-up, similar in both groups, is 25.9 months (SD [standard deviation]: 8.4 months). RESULTS: At 2 years, the estimated cumulative incidence of grade 2 late rectal toxicity is 6%+/-4% for WP-IMRT/PB and 21.2%+/-6% for P-3D-CRT (p=0.06). The difference became significant (HR [hazard ratio]=0.1, 95% CI [confidence interval]: 0.0-0.6; p=0.01) at multivariate analysis. None of the patients developed grade 3+ toxicity. CONCLUSION: Despite the larger treated volume, WP-IMRT/PB allows more rectal sparing than P-3D-CRT.
Authors:
Giuseppe Sanguineti; Matthew L Cavey; Eugene J Endres; Paola Franzone; Salvina Barra; Brent C Parker; Michela Marcenaro; Martin Colman; Stefano Agostinelli; Franca Foppiano; Vito Vitale
Related Documents :
19577867 - Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent tax...
11165677 - Cervical tumor control evaluated with icru 38 reference volumes and integrated referenc...
14606097 - Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic ...
18426607 - Conventionally-fractionated image-guided intensity modulated radiotherapy (ig-imrt): a ...
16327487 - Frozen sectioning of the pancreatic cut surface during resection of intraductal papilla...
23205787 - Validation of recursive partitioning analysis and diagnosis-specific graded prognostic ...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]     Volume:  182     ISSN:  0179-7158     ISO Abbreviation:  Strahlenther Onkol     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-08-31     Completed Date:  2006-11-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8603469     Medline TA:  Strahlenther Onkol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  543-9     Citation Subset:  IM    
Affiliation:
Department of Radiation Oncology, University of Texas Medical Branch, Galveston, TX 77555-0711, USA. gisangui@utmb.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Actuarial Analysis
Aged
Data Interpretation, Statistical
Dose Fractionation
Follow-Up Studies
Humans
Lymph Nodes / radiation effects*
Male
Pelvis
Prospective Studies
Prostatic Neoplasms / radiotherapy*
Radiotherapy Dosage*
Radiotherapy, Conformal*
Radiotherapy, Intensity-Modulated*
Rectum / radiation effects*
Time Factors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long-term results in three-dimensional conformal radiotherapy of localized prostate cancer at modera...
Next Document:  Pain and quality of life following palliative radiotherapy of bone metastases